Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology [Yahoo! Finance]
Dyadic International, Inc. (DYAI)
NASDAQ:AMEX Investor Relations:
dyadic.com
Company Research
Source: Yahoo! Finance
JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates Foundation for the cell line development of monoclonal antibodies (mAbs) targeting respiratory syncytial virus (RSV) and malaria utilizing the company's proprietary C1 protein production platform to provide globally accessible treatment options for underserved populations. RSV is a major cause of lower respiratory tract infection morbidity and mortality in children globally, causing 3.2–36 million hospitalizations and more than 100,000 deaths annually, 99% of which occur in low-income and middle-income countries (LMICs). In 2022, there were an estimated 249 million malaria cases and 608,000 malaria deaths globally, with the WHO African Region accounting for 94% of cases and 95% of deaths. “Thanks to this new grant from the Gates Foundation, we are advancing our C1 platform to develop
Show less
Read more
Impact Snapshot
Event Time:
DYAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYAI alerts
High impacting Dyadic International, Inc. news events
Weekly update
A roundup of the hottest topics
DYAI
News
- Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform TechnologyGlobeNewswire
- Dyadic International Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Dyadic International, Inc. (NASDAQ: DYAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Dyadic International Inc (DYAI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]Yahoo! Finance
- Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key MarketsGlobeNewswire
DYAI
Earnings
- 11/12/24 - Beat
DYAI
Analyst Actions
- 11/14/24 - HC Wainwright
DYAI
Sec Filings
- 12/20/24 - Form 144
- 11/26/24 - Form 8-K
- 11/25/24 - Form 4
- DYAI's page on the SEC website